News Updates

More Articles Back to Article

Nivolumab gains NICE backing for rare gastroesophageal cancers

The UK's National Institute of Health and Care Excellence has recommended Bristol Myers Squibb's Opdivo, or nivolumab, as a first-line treatment, combined with chemotherapy, to treat rare forms of advanced gastroesophageal cancer such as untreated HER2-negative, advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma if the tumors express PD-L1 with combined positive scores of five or greater. The recommendation was based on clinical results of the CheckMate-649 trial that showed use of Opdivo, combined with CapeOX or FOLFOX chemotherapy, resulted in substantial improvements in progression-free and overall survival. PMLive (UK) (11/25)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!